| Type 2 Diabetes Mellitus |
1 |
1 |
| GLP-1 Receptor Agonist |
0 |
0.74 |
| Chronic Kidney Disease |
0 |
0.57 |
| Renal Failure |
0 |
0.57 |
| Renal Disease |
0 |
0.52 |
| Kidney |
0 |
0.55 |
| Receptors |
0 |
0.49 |
| Obesity |
0 |
0.42 |
| Heart Failure (HF) |
0 |
0.41 |
| Cardiovascular Imaging |
0 |
0.4 |
| SGLT2 Inhibitor |
0 |
0.32 |
| Hemodialysis |
0 |
0.31 |
| Hypertension |
0 |
0.3 |
| Cardiovascular Risk Management |
0 |
0.28 |
| Heart |
0 |
0.28 |
| Ejection Fraction |
0 |
0.22 |
| Weight Loss |
0 |
0.21 |
| Weight Management |
0 |
0.2 |
| Adverse Effects |
0 |
0.18 |
| Patient Safety |
0 |
0.17 |
| Hemoglobin A1c |
0 |
0.11 |
| Cerebrovascular Accident |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Dyslipidemia |
0 |
0.07 |
| Endocrinology |
0 |
0.07 |
| Hyperkalemia |
0 |
0.07 |
| Incretin Hormone |
0 |
0.07 |
| Lipids Management |
0 |
0.07 |
| Metabolism |
0 |
0.07 |
| Nausea |
0 |
0.07 |
| Thyroid Disease |
0 |
0.06 |
| Cardiovascular disease |
0 |
0.04 |
| Evidence-Based Medicine |
0 |
0.04 |
| Fellowship |
0 |
0.04 |
| Food and Drug Administration (FDA) |
0 |
0.04 |
| Hypotension |
0 |
0.04 |
| Medical Education |
0 |
0.04 |
| Meta-Analysis |
0 |
0.04 |
| Refractory |
0 |
0.04 |
| Renal Replacement Therapy |
0 |
0.04 |
| Residency |
0 |
0.04 |
| Thyroid |
0 |
0.04 |